Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab

By sjmartinez • August 30, 2024

Shen YC, Liu TH, Nicholas A, Soyama A, Yuan CT, Chen TC, Eguchi S, Yoshizumi T, Itoh S, Nakamura N, Kosaka H, Kaibori M, Ishii T, Hatano E, Ogawa C, Naganuma A, Kakizaki S, Cheng CH, Lin PT, Su YY, Chuang CH, Lu LC, Wu CJ, Wang HW, Rau KM, Hsu CH, Lin SM, Huang YH, Hernandez S, Finn RS, Kudo M, Cheng AL. Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab. J Clin Oncol. 2024 Aug 28:JCO2400645. doi: 10.1200/JCO.24.00645. Epub ahead of print. PMID: 39197119.

Tags: Hematology/Oncology, Publications

Related Posts

A Pilot Test of an AI Voice-Driven Simulation With Feedback for Medical Students to Practice Discussing Diagnostic Mammogram Results With Patients

Comulada WS, Ganz PA, Huang YM, Weisman D, Sugarman A, Lee D, Shah S, Gelberg L. A Pilot Test of an AI Voice-Driven Simulation With[...]

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival

Crown J, Stroyakovskii D, Yardley DA, Huang CS, Fasching PA, Bardia A, Chia S, Im SA, Martin M, Xu B, Barrios CH, Untch M, Moroose[...]

Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy

Wang Y, Guan Y, Abbas AR, Sano Y, Jain S, Lu S, Hamidi H, Koeppen H, Azuma Y, Kayukawa Y, Shinozuka J, Pochiraju A, Webster[...]